Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer's Disease.
Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer's Disease.
复制标题
抗 Aβ 抗体片段的应用，重点是与纳米颗粒联合应用治疗阿尔茨海默病
DOI：
10.3389/fphar.2021.654611
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Wang X
中科院分区：
文献类型：
--
作者：
Sun ZT;Ma C;Li GJ;Zheng XY;Hao YT;Yang Y;Wang X
阿尔茨海默病（Alzheimer's disease，AD）是最常见的神经退行性疾病之一，越来越多的证据表明β淀粉样蛋白（amyloid-β，Aβ）在AD的发病机制中起着重要作用。根据淀粉样蛋白级联假说，产生和清除Aβ的失衡是神经变性和痴呆的开始。因此，通过使用抗Aβ的抗体进行免疫治疗变得流行。然而，许多单克隆抗体的研究被停止，因为出现了不良反应或没有观察到明显的益处。与单克隆抗体相比，抗体片段具有体积小、不含Fc等优点，主要有单链抗体片段、Fab抗体片段和单域抗体片段。纳米颗粒可以促进药物分子穿过血脑屏障，使其成为优良的载体。各种纳米颗粒已被应用于AD的治疗。纳米颗粒和抗淀粉样蛋白-β抗体片段的组合可用于阿尔茨海默病的诊断和治疗。本文综述了抗β淀粉样蛋白抗体片段在AD中的研究进展，重点介绍了其与纳米粒在AD诊断和治疗中的联合应用。
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases and accumulating evidences suggest a key role of amyloid-β (Aβ) peptide in the pathogenesis of AD. According to the amyloid cascade hypothesis, the imbalance of producing and clearing Aβ is the beginning of neurodegeneration and dementia. Consequently, immunotherapy becomes popular through using antibodies against Aβ. However, many studies of monoclonal antibodies were stopped because adverse effects appeared or there were no evident benefits observed. Some antibody fragments have many advantages over monoclonal antibodies, such as small sizes, lack of the crystallizable fraction (Fc) and so on. There are three main antibody fragments, including single chain variable fragments (scFvs), Fab fragments and single-domain antibody fragments. Nanoparticles can facilitate the entry of drug molecules across the blood-brain barrier, making them become excellent carriers. Various kinds of nanoparticles have been applied in the treatment of AD. The combination of nanoparticles and antibody fragments against amyloid-β can be used in the diagnosis and treatment of Alzheimer’s disease. In this review, we summarize the progress of antibody fragments against amyloid-β in AD, focusing on the combined application with nanoparticles in the diagnosis and treatment of AD.
登录
查看更多内容
DOI：
10.3233/jad-2011-110230
发表时间：
2011
期刊：
Journal of Alzheimer's disease : JAD
影响因子：
--
作者：
Kou J;Kim H;Pattanayak A;Song M;Lim JE;Taguchi H;Paul S;Cirrito JR;Ponnazhagan S;Fukuchi K
通讯作者：
Fukuchi K
影响因子：
3.7
作者：
Esquerda-Canals, Gisela;Marti-Clua, Joaquim;Villegas, Sandra
通讯作者：
Villegas, Sandra
影响因子：
4
作者：
Esquerda-Canalsa, Gisela;Roda, Alejandro R.;Villegas, Sandra
通讯作者：
Villegas, Sandra
影响因子：
2.9
作者：
Kasturirangan, Srinath;Reasoner, Tim;Schulz, Philip;Boddapati, Shanta;Emadi, Sharareh;Valla, Jon;Sierks, Michael R.
通讯作者：
Sierks, Michael R.
影响因子：
3.7
作者：
Agyare, Edward K.;Curran, Geoffry L.;Ramakrishnan, Muthu;Yu, Caroline C.;Poduslo, Joseph F.;Kandimalla, Karunya K.
通讯作者：
Kandimalla, Karunya K.